---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-292625"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2022-11-25T23:59:59+00:00"
generated_at: "2026-06-21T12:59:03.727388+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaccinex raises $3.8M via private placement of 7.14M shares at $0.5293 per share

## Summary
- Issued 7,142,496 shares to accredited investors for gross proceeds of ~$3.8 million.
- Insider participation: CEO Maurice Zauderer, chairman Albert Friedberg, directors Jacob Frieberg and Gerald Van Strydonck.
- Proceeds to fund pepinemab clinical trials and for working capital.
- Registration rights agreement filed to register shares for resale within 75 days after closing.
- Shares sold under Section 4(a)(2) and Rule 506 of Regulation D.

## SEC filing metadata
- accession: 0001193125-22-292625
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2022-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/0001193125-22-292625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/d391207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-292625
- JSON: https://secwatch.observer/filing/0001193125-22-292625.json
- Plain text: https://secwatch.observer/filing/0001193125-22-292625.txt

## Key facts
- Material Agreements
  VACCINEX, INC. entered into Registration Rights Agreement with certain of the Investors (effective 2022-11-22).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain of the Investors
  - Effective: 2022-11-22
  source text: On November 22, 2022, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain of the Investors that affords such Investors certain registration rights with respect to the Shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/0001193125-22-292625-index.htm
- Material Agreements
  VACCINEX, INC. entered into Stock Purchase Agreement with the investors named therein valued at approximately $3.8 million (effective 2022-11-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investors named therein
  - Value: approximately $3.8 million
  - Effective: 2022-11-18
  source text: On November 18, 2022, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the investors named therein an aggregate of 6,112,031 shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), at a purchase price of $0.5293 per Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/0001193125-22-292625-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.